Afrezza (INHALE-1)

Overview:
This study evaluates the safety and effectiveness of an inhaled short-acting insulin in children.
Staus:
Closed
Clinical Description:
This study is evaluating the efficacy and safety of Afrezza, an inhaled insulin, in combination with a basal insulin versus insulin aspart or insulin lispro in combination with a basal insulin in pediatric subjects with type 1 or type 2 diabetes mellitus.
Target Age/Sex:
Over 4 years and under 18, Male & Female (on multiple daily injections)
Benefits:
Participants will receive at no cost: study product, study materials and study-specific procedures.
Study Length:
About 56 Weeks
Link:
ClinicalTrials.gov
This Study is Closed.